Accelrys and eMolecules Collaborate to Enhance Accelrys Available Chemicals Directory
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130402:nPnMM86932 Validated and curated in-stock compounds from eMolecules now accessible through Accelrys ACD SAN DIEGO and SOLANA BEACH, Calif., April 2, 2013 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, and eMolecules, Inc, a market-leading compound sourcing platform, announced that they are collaborating to include eMolecules' in-stock building block compounds in the Accelrys Available Chemicals Directory (ACD) database. Adding eMolecules into Accelrys ACD enables scientists to identify the optimal set of compounds for their synthesis or library with increased confidence that those compounds will be available at the indicated prices from the selected suppliers. To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-and-emolecules-collaborate-to-enhance-accelrys-available-chemicals-directory-200976961.html "Now, with the inclusion of validated and curated compound availability information from eMolecules, Accelrys ACD customers can order with increased confidence that chemical suppliers will deliver the compounds on time," said Dr. Matt Hahn, senior vice president and chief technology officer, Accelrys. "Together, Accelrys and eMolecules are revolutionizing the efficiency and reliability of compound acquisition throughout our shared markets." "This collaboration will help Accelrys ACD users acquire the in-stock compounds critical to their projects' progress in an efficient and easy way," said Niko Gubernator, CEO of eMolecules. "eMolecules is excited to demonstrate to Accelrys' ACD users how our revolutionary approach to compound purchasing has delivered industry-proven results in improving efficiencies, lowering costs and driving innovation for pharmaceutical, biotech and academic groups alike." The eMolecules online chemical compound sourcing platform has rapidly established itself as a market leader in enabling scientists to source and purchase commercially available 'in-stock' compounds reliably and efficiently. Accelrys ACD, used and trusted for more than 25 years by researchers in the global pharmaceutical, biotechnology, chemical and agrochemical sectors, enables scientists to access high quality curated and harmonized chemical property, availability and pricing information on 7.8 million compounds from 940 suppliers, with the information available via numerous delivery mechanisms including remotely hosted services. As a result of the collaboration between Accelrys and eMolecules, ACD compounds now include more than 580,000 in-stock building blocks from more than 200 trusted eMolecules suppliers. With the inclusion of the unique eMolecules compound identifiers in ACD, and the equivalent unique ACD identifiers in the eMolecules catalog, ACD users can now prepare their order list using ACD and then quickly, easily and confidently order their compounds from multiple suppliers using the eMolecules fulfillment service. The eMolecules platform enables scientists to obtain real-time information on ready-to-be-shipped compounds and access online management tools for tracking orders and determining delivery times. To learn more about Accelrys ACD, visit the ACD product page at the Accelrys website. About eMolecules eMolecules was founded by scientists for scientists in 2005 with one goal in mind: reduce drug discovery timelines through improved efficiencies. eMolecules has built a powerful chemical search engine combined with customized online ordering and integrated logistics to source in-stock screening compounds and building blocks from more than 200 suppliers. The result is an improved compound acquisition workflow that brings benefits to all types of organizations: with 9 out of 10 large pharmaceutical companies, 4 out of 5 large biotechs and dozens of small biotech and academic groups working with eMolecules. For more information about eMolecules, visit www.emolecules.com About Accelrys Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market. Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com. Related Links Accelrys Website Follow Accelrys on Twitter Friend Accelrys on Facebook Accelrys' YouTube Channel Connect with Accelrys on LinkedIn SOURCE Accelrys, Inc. Niko Gubernator, CEO, eMolecules Inc., 858-764-1941, firstname.lastname@example.org; Racepoint Group, For Accelrys, Susan Thomas, 619-540-9195, email@example.com
- Malaysia air probe finds scant evidence of attack: sources |
- Malaysia air probe finds scant evidence of attack: sources |
- Exclusive: Chinese raw materials also found on U.S. B-1 bomber, F-16 jets
- Governor Christie's trustworthiness takes a hit in New Jersey poll
- Confrontation in Ukraine as diplomacy stalls |